Johnson & Johnson (JNJ) Shares Issued (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Shares Issued came in at $1.2 billion in Q1 2026, up 160.44% year-on-year from $450.0 million in Q1 2025, and down 26.15% quarter-over-quarter from $1.6 billion in Q4 2025.
Johnson & Johnson (JNJ) Shares Issued (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Shares Issued across 18 years of filings, most recently posting $1.2 billion for Q1 2026.
- Shares Issued for Q1 2026 came in at $1.2 billion, up 160.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 1523.53% YoY), and the FY2025 annual result was $3.4 billion, changed N/A from the prior year.
- Shares Issued came in at $1.2 billion for Q1 2026 at Johnson & Johnson, down from $1.6 billion in the prior quarter.
- In the past five years, Shares Issued ranged from a high of $4.3 billion in Q3 2023 to a low of -$3.3 billion in Q4 2023.
- The 5-year median for Shares Issued is $195.0 million (2024), against an average of $346.5 million.
- Peak annual rise in Shares Issued reached 1872.73% in 2024, while the deepest fall reached 481.82% in 2024.
- Johnson & Johnson's Shares Issued stood at $321.0 million in 2022, then sank by 41.74% to $187.0 million in 2023, then tumbled by 481.82% to -$714.0 million in 2024, then surged by 322.27% to $1.6 billion in 2025, then retreated by 26.15% to $1.2 billion in 2026.
- The last three Shares Issued figures came in at $1.2 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 10.79 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.17 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 157.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 166.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 1.17 Bn |
| Mar 29, 2026 | 1.17 Bn |
| Dec 28, 2025 | 1.59 Bn |
| Dec 28, 2025 | 1.59 Bn |
| Sep 28, 2025 | 1.27 Bn |
| Sep 28, 2025 | 1.27 Bn |
| Jun 29, 2025 | 107.00 Mn |
| Jun 29, 2025 | 107.00 Mn |
| Mar 30, 2025 | 450.00 Mn |
| Mar 30, 2025 | 450.00 Mn |
| Dec 29, 2024 | -714.00 Mn |
| Dec 29, 2024 | -714.00 Mn |
| Sep 29, 2024 | 424.00 Mn |
| Sep 29, 2024 | 424.00 Mn |
| Jun 30, 2024 | 95.00 Mn |
| Jun 30, 2024 | 95.00 Mn |
| Mar 31, 2024 | 195.00 Mn |
| Mar 31, 2024 | 195.00 Mn |
| Dec 31, 2023 | 187.00 Mn |
| Dec 31, 2023 | 187.00 Mn |